CBIO · Crescent Biopharma Inc. Common Stock
View on chartInsiders & Stakes
| Invus Public Equities, L.P. 10% Owner | ▼ Sell | Open Market | 6,317,565 Shares held | 8/8/2024 | View profile |
| Fairmount Funds Management LLC Director | ▲ Buy | Open Market | 3,601,316 Shares held | 7/16/2026 | View profile |
| Scott D. Sandell 10% Owner | ▼ Sell | Open Market | 2,237,196 Shares held | 1/26/2023 | View profile |
| Edwin Rock Chief Medical Officer | ▲ Buy | Open Market | 680,403 Shares held | 6/21/2024 | View profile |
| King Rachel K. Director | ▲ Buy | Grant | 515,194 Shares held | 3/29/2024 | View profile |
| Magnani John L. SVP of Research, CSO | ▲ Buy | Open Market | 366,078 Shares held | 11/11/2022 | View profile |
| Joshua T. Brumm Chief Executive Officer | ▼ Sell | Open Market | 271,765 Shares held | 9/18/2026 | View profile |
| Johnson Bruce S SVP & Chief Commercial Officer | ▲ Buy | Open Market | 138,980 Shares held | 5/8/2023 | View profile |
| Jonathan McNeill President and COO | ▼ Sell | Open Market | 134,588 Shares held | 9/18/2026 | View profile |
| Daniel M. Junius Director | ▲ Buy | Grant | 98,459 Shares held | 3/29/2024 | View profile |
| Brian M. Hahn SVP Finance, CFO | ▲ Buy | Open Market | 70,643 Shares held | 6/18/2024 | View profile |
| BVF PARTNERS L P/IL 10% Owner | ▼ Sell | Other | 62,383 Shares held | 6/13/2025 | View profile |
| Christopher Grant Doughty Chief Business Officer | ▲ Buy | Grant | 62,194 Shares held | 12/15/2025 | View profile |
| Patricia S. Andrews Director | ▲ Buy | Grant | 58,608 Shares held | 12/29/2023 | View profile |
| Koenig Scott President and CEO | ▲ Buy | Option Exercise | 36,750 Shares held | 6/1/2023 | View profile |
| Girard Armand SVP, Chief Business Officer | ▲ Buy | Open Market | 29,161 Shares held | 11/11/2022 | View profile |
| Semerjian Harout Chief Executive Officer | ▲ Buy | Open Market | 25,000 Shares held | 11/11/2022 | View profile |
| Goldberg Mark Alan Director | ▲ Buy | Grant | 24,828 Shares held | 3/29/2024 | View profile |
| PEARSON TIMOTHY R Director | ▲ Buy | Open Market | 24,650 Shares held | 11/11/2022 | View profile |
| Jan Pinkas Chief Scientific Officer | ▼ Sell | Open Market | 21,581 Shares held | 9/16/2026 | View profile |
| Ellie Eunkyung Im Chief Medical Officer | ▼ Sell | Open Market | 21,446 Shares held | 9/16/2026 | View profile |
| Richard William Scalzo Chief Financial Officer | ▼ Sell | Open Market | 19,730 Shares held | 9/16/2026 | View profile |
| Barbara Harlin Bispham See Remarks | ▼ Sell | Open Market | 18,710 Shares held | 9/16/2026 | View profile |
| Ryan Lynch See Remarks | ▼ Sell | Open Market | 13,631 Shares held | 9/16/2026 | View profile |
Transaction History
| Joshua T. Brumm | ▼ Sell | Open Market | 7,837 | $131K | 9/18/2026 |
| Jonathan McNeill | ▼ Sell | Open Market | 3,839 | $64K | 9/18/2026 |
| Ryan Lynch | ▼ Sell | Open Market | 240 | $4K | 9/16/2026 |
| Jan Pinkas | ▼ Sell | Open Market | 658 | $12K | 9/16/2026 |
| Ellie Eunkyung Im | ▼ Sell | Open Market | 623 | $11K | 9/16/2026 |
| Richard William Scalzo | ▼ Sell | Open Market | 568 | $10K | 9/16/2026 |
| Barbara Harlin Bispham | ▼ Sell | Open Market | 620 | $11K | 9/16/2026 |
| Joshua T. Brumm | ▼ Sell | Open Market | 1,610 | $29K | 9/16/2026 |
| Jonathan McNeill | ▼ Sell | Open Market | 731 | $13K | 9/16/2026 |
| Fairmount Funds Management LLC | ▲ Buy | Open Market | 853,450 | $12.4M | 7/16/2026 |
| Ryan Lynch | ▼ Sell | Open Market | 465 | $8K | 6/22/2026 |
| Jan Pinkas | ▼ Sell | Open Market | 1,288 | $23K | 6/22/2026 |
| Richard William Scalzo | ▼ Sell | Open Market | 1,112 | $20K | 6/22/2026 |
| Barbara Harlin Bispham | ▼ Sell | Open Market | 1,218 | $22K | 6/22/2026 |
| Ellie Eunkyung Im | ▼ Sell | Open Market | 1,219 | $22K | 6/22/2026 |
| Jonathan McNeill | ▼ Sell | Open Market | 20,549 | $370K | 6/22/2026 |
| Joshua T. Brumm | ▼ Sell | Open Market | 42,305 | $761K | 6/22/2026 |
| Jan Pinkas | ▲ Buy | Grant | 17,507 | — | 12/15/2025 |
| Jan Pinkas | ▲ Buy | Grant | 5,000 | — | 12/15/2025 |
| Christopher Grant Doughty | ▲ Buy | Grant | 14,714 | — | 12/15/2025 |
| Christopher Grant Doughty | ▲ Buy | Grant | 8,000 | — | 12/15/2025 |
| Joshua T. Brumm | ▲ Buy | Grant | 45,117 | — | 12/15/2025 |
| Joshua T. Brumm | ▲ Buy | Grant | 10,000 | — | 12/15/2025 |
| Richard William Scalzo | ▲ Buy | Grant | 14,422 | — | 12/15/2025 |
| Richard William Scalzo | ▲ Buy | Grant | 5,000 | — | 12/15/2025 |
| Jonathan McNeill | ▲ Buy | Grant | 19,507 | — | 12/15/2025 |
| Jonathan McNeill | ▲ Buy | Grant | 6,000 | — | 12/15/2025 |
| Ellie Eunkyung Im | ▲ Buy | Grant | 16,298 | — | 12/15/2025 |
| Ellie Eunkyung Im | ▲ Buy | Grant | 5,000 | — | 12/15/2025 |
| Ryan Lynch | ▲ Buy | Grant | 8,378 | — | 12/15/2025 |
| Ryan Lynch | ▲ Buy | Grant | 4,000 | — | 12/15/2025 |
| Barbara Harlin Bispham | ▲ Buy | Grant | 12,422 | — | 12/15/2025 |
| Barbara Harlin Bispham | ▲ Buy | Grant | 6,000 | — | 12/15/2025 |
| Fairmount Funds Management LLC | ▲ Buy | Open Market | 1,360,000 | $18.2M | 12/4/2025 |
| BVF PARTNERS L P/IL | ▼ Sell | Other | 657,308 | — | 6/13/2025 |
| BVF PARTNERS L P/IL | ▼ Sell | Other | 556,617 | — | 6/13/2025 |
| BVF PARTNERS L P/IL | ▼ Sell | Other | 56,079 | — | 6/13/2025 |
| Invus Public Equities, L.P. | ▼ Sell | Open Market | 260,873 | $50K | 8/8/2024 |
| Invus Public Equities, L.P. | ▼ Sell | Open Market | 61,488 | $11K | 8/7/2024 |
| Invus Public Equities, L.P. | ▼ Sell | Open Market | 55,732 | $10K | 8/6/2024 |
| Invus Public Equities, L.P. | ▼ Sell | Open Market | 164,523 | $31K | 8/5/2024 |
| Invus Public Equities, L.P. | ▼ Sell | Open Market | 286,200 | $57K | 8/2/2024 |
| Invus Public Equities, L.P. | ▼ Sell | Open Market | 63,564 | $14K | 8/1/2024 |
| Invus Public Equities, L.P. | ▼ Sell | Open Market | 756,835 | $167K | 7/30/2024 |
| Invus Public Equities, L.P. | ▼ Sell | Open Market | 363,949 | $86K | 7/29/2024 |
| Invus Public Equities, L.P. | ▼ Sell | Open Market | 258,335 | $62K | 7/26/2024 |
| Edwin Rock | ▲ Buy | Open Market | 115,000 | $31K | 6/21/2024 |
| Edwin Rock | ▲ Buy | Open Market | 190,000 | $48K | 6/20/2024 |
| Brian M. Hahn | ▲ Buy | Open Market | 17,500 | $4K | 6/18/2024 |
| Daniel M. Junius | ▲ Buy | Grant | 5,209 | $16K | 3/29/2024 |
| Goldberg Mark Alan | ▲ Buy | Grant | 4,584 | $14K | 3/29/2024 |
| King Rachel K. | ▲ Buy | Grant | 3,334 | $10K | 3/29/2024 |
| Patricia S. Andrews | ▲ Buy | Grant | 5,191 | $12K | 12/29/2023 |
| King Rachel K. | ▲ Buy | Grant | 4,238 | $10K | 12/29/2023 |
| Goldberg Mark Alan | ▲ Buy | Grant | 5,827 | $14K | 12/29/2023 |
| Goldberg Mark Alan | ▲ Buy | Grant | 9,167 | $14K | 9/30/2023 |
| Patricia S. Andrews | ▲ Buy | Grant | 8,167 | $12K | 9/30/2023 |
| King Rachel K. | ▲ Buy | Grant | 6,667 | $10K | 9/30/2023 |
| Edwin Rock | ▲ Buy | Open Market | 30,403 | $42K | 9/22/2023 |
| Edwin Rock | ▲ Buy | Open Market | 35,000 | $48K | 9/21/2023 |
| Koenig Scott | ▲ Buy | Option Exercise | 21,000 | $13K | 6/1/2023 |
| Brian M. Hahn | ▼ Sell | Open Market | 3,700 | $7K | 5/17/2023 |
| Daniel M. Junius | ▲ Buy | Open Market | 30,000 | $47K | 5/10/2023 |
| Johnson Bruce S | ▲ Buy | Open Market | 13,500 | $21K | 5/8/2023 |
| Invus Public Equities, L.P. | ▲ Buy | Open Market | 100,000 | $170K | 2/24/2023 |
| Invus Public Equities, L.P. | ▲ Buy | Open Market | 200,000 | $351K | 2/23/2023 |
| Invus Public Equities, L.P. | ▲ Buy | Open Market | 150,000 | $269K | 2/22/2023 |
| Invus Public Equities, L.P. | ▲ Buy | Open Market | 50,000 | $93K | 2/21/2023 |
| Invus Public Equities, L.P. | ▲ Buy | Open Market | 200,000 | $341K | 2/17/2023 |
| Invus Public Equities, L.P. | ▲ Buy | Open Market | 315,266 | $531K | 2/16/2023 |
| Invus Public Equities, L.P. | ▲ Buy | Open Market | 1,000,000 | $2.2M | 2/15/2023 |
| Invus Public Equities, L.P. | ▲ Buy | Open Market | 11,451 | $37K | 2/9/2023 |
| Koenig Scott | ▲ Buy | Option Exercise | 10,500 | $27K | 1/27/2023 |
| Scott D. Sandell | ▼ Sell | Open Market | 1,648,908 | $5.1M | 1/26/2023 |
| Scott D. Sandell | ▼ Sell | Open Market | 1,351,092 | $4.2M | 1/26/2023 |
| Scott D. Sandell | ▼ Sell | Open Market | 293,645 | $958K | 1/25/2023 |
| Scott D. Sandell | ▼ Sell | Open Market | 358,371 | $1.2M | 1/25/2023 |
| Scott D. Sandell | ▼ Sell | Open Market | 32,139 | $89K | 1/5/2023 |
| Scott D. Sandell | ▼ Sell | Open Market | 39,223 | $108K | 1/5/2023 |
| Scott D. Sandell | ▼ Sell | Open Market | 56,054 | $163K | 1/4/2023 |
| Scott D. Sandell | ▼ Sell | Open Market | 45,930 | $134K | 1/4/2023 |
| Scott D. Sandell | ▼ Sell | Open Market | 78,730 | $235K | 1/3/2023 |
| Scott D. Sandell | ▼ Sell | Open Market | 96,084 | $287K | 1/3/2023 |
| Scott D. Sandell | ▼ Sell | Open Market | 66,690 | $201K | 12/30/2022 |
| Scott D. Sandell | ▼ Sell | Open Market | 54,645 | $165K | 12/30/2022 |
| Edwin Rock | ▲ Buy | Open Market | 110,000 | $248K | 12/22/2022 |
| Daniel M. Junius | ▲ Buy | Open Market | 20,000 | $37K | 11/17/2022 |
| Edwin Rock | ▲ Buy | Open Market | 100,000 | $166K | 11/15/2022 |
| Edwin Rock | ▲ Buy | Open Market | 100,000 | $143K | 11/14/2022 |
| PEARSON TIMOTHY R | ▲ Buy | Open Market | 19,400 | $25K | 11/11/2022 |
| Semerjian Harout | ▲ Buy | Open Market | 25,000 | $32K | 11/11/2022 |
| Girard Armand | ▲ Buy | Open Market | 6,500 | $7K | 11/11/2022 |
| Brian M. Hahn | ▲ Buy | Open Market | 20,000 | $21K | 11/11/2022 |
| Magnani John L. | ▲ Buy | Open Market | 45,045 | $53K | 11/11/2022 |
| Magnani John L. | ▼ Sell | Open Market | 3,227 | $4K | 3/9/2022 |
| Girard Armand | ▼ Sell | Open Market | 2,339 | $3K | 3/9/2022 |
| Brian M. Hahn | ▼ Sell | Open Market | 2,917 | $3K | 3/9/2022 |
| Patricia S. Andrews | ▲ Buy | Open Market | 40,000 | $82K | 11/16/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
CBIO Announces New Clinical Trial Milestones for CR-001
Crescent Biopharma said it is enrolling patients in the standard‑of‑care chemotherapy arms of its global Phase 1/2 ASCEND trial for CR‑001, a PD‑1 × VEGF bispecific antibody. The company also began additional antibody‑drug‑conjugate combination studies with CR‑001. These steps indicate progress in the drug’s development and broaden its potential clinical applications.
CBIO Announces New Clinical Trial Milestones for CR-001. Crescent Biopharma said it is enrolling patients in the standard‑of‑care chemotherapy arms of its global Phase 1/2 ASCEND trial for CR‑001, a PD‑1 × VEGF bispecific antibody. The company also began additional antibody‑drug‑conjugate combination studies with CR‑001. These steps indicate progress in the drug’s development and broaden its potential clinical applications.